-
Matching-Adjusted Indirect Comparisons (MAICs) and Network Meta-Analyses (NMAs) of the Oral Small-Molecule Chaperone Migalastat vs. Intravenous Enzyme Replacement Therapies (ERTs) for Clinical Measures in Fabry Disease
Sep 9, 2025, 16:22 PM -
Cost of Adverse Events With the Bruton Tyrosine Kinase Inhibitors Ibrutinib and Acalabrutinib in the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia in Brazil
Sep 9, 2025, 16:22 PM -
A Review of Cost Comparisons Submitted to NICE Since the Introduction of the Proportional Approach to Technology Appraisal
Sep 9, 2025, 16:22 PM -
Characterizing the Use of Janus Kinase Inhibitors (JAKi) in Five European Countries: A Drug Utilization Study
Sep 9, 2025, 16:22 PM -
Economic Burden Associated With Type 2 Diabetes Mellitus in France: An Update From the National Insurance Claim Database
Sep 9, 2025, 16:22 PM -
Evaluating the Cost-Effectiveness of Adjuvanted Influenza Vaccine in the Older Adult Population in the Netherlands
Sep 9, 2025, 16:22 PM -
The Use of Dynamic Models in Economic Evaluations in the UK and France
Sep 9, 2025, 16:22 PM -
Citizens’ Send Messages to Policy Makers Related to Primary Healthcare Practices: First Results From the Implementation of the Patient-Reported Indicator Surveys PaRIS in Greece
Sep 9, 2025, 16:22 PM -
Health-Related Quality of Life in Adults With Dry Eye Disease in France: Insights From a Multicenter Observational Study
Sep 9, 2025, 16:22 PM -
Medium vs. Low Citrate Concentration in Continuous Kidney Replacement Therapy: Positive Budget Impact Through Total Cost of Ownership Assessment
Sep 9, 2025, 16:22 PM -
Differential Responsiveness and Minimally Important Difference of EQ-5D: Truth or Artifact?
Sep 9, 2025, 16:22 PM -
Use of a Nonparametric Bayesian Method to Model Health State Preferences: An Application to UAE EQ-5D-5L Valuations
Sep 9, 2025, 16:22 PM -
Signal Detection and Network Pharmacology Analysis of Paronychia Associated With eGFR Inhibitors
Sep 9, 2025, 16:22 PM -
Life-Years Lost Due to Regulatory and Reimbursement Delays: A Study of Oncology Drugs Across England, Scotland, and France, 2022-2024
Sep 9, 2025, 16:22 PM -
Underlying Systemic Motifs That Prevent Diabetes Patients From Seeking and Utilizing Health Services in a Country With a High Prevalence of Diabetes
Sep 9, 2025, 16:22 PM -
The Elusive PICO: Assessing Prediction in Joint Clinical Assessments (JCA): A Case Study in Soft Tissue Sarcoma (STS)
Sep 9, 2025, 16:22 PM -
Integrating Prospective and Retrospective Real-World Data to Construct External Comparator Arms: Novel Methods and Design Considerations
Sep 9, 2025, 16:22 PM -
Mobility and Upper Extremity Function in Duchenne Muscular Dystrophy: A Longitudinal Survey Using PROMIS
Sep 9, 2025, 16:22 PM -
The New Avenue for Access? European Market Access Routes Outside Traditional Public Payer Pathways
Sep 9, 2025, 16:22 PM -
What Are the Likely PICOs for Tovorafenib and Lifileucel as the First Products to Go Through the JCA?
Sep 9, 2025, 16:22 PM
